3P Biopharmaceuticals and Norwegian biopharmaceutical company, Nordic Nanovector, have extended their collaboration agreement for the development of Betalutin. The two companies started their collaboration in 2013 and successfully advanced Betalutin. The current agreement is consolidating the relationship describing how both companies will progress the project up to regulatory submission, including development, clinical supply and late stage activities, such as process characterization and valid...